- Conditions
- Migraines
- Interventions
- divalproex sodium
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- North Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 133
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Migraine or Episodic Migraine
- Interventions
- Placebo, AMG 301
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 21
- States / cities
- Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more
- Conditions
- Migraine Headache
- Interventions
- Aricept (donepezil hydrochloride)
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Springfield, Missouri • Mount Vernon, New York + 1 more
- Conditions
- Chronic Migraine
- Interventions
- Xeomin, Placebo
- Drug
- Lead sponsor
- Merz Therapeutics GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 780 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 48
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 42 more
- Conditions
- Menstrually Associated Migraine
- Interventions
- Frovatriptan, Placebo
- Drug
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 579 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 1
- States / cities
- Chadds Ford, Pennsylvania
- Conditions
- Migraine
- Interventions
- Erenumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 955 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Anaheim, California • Encino, California + 55 more
- Conditions
- Chronic Migraine, Chronic Migraine, Headache, Chronic Migraine Without Aura, Aura Migraine
- Interventions
- TNX-1900, Placebo Nasal Spray
- Drug
- Lead sponsor
- Tonix Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • Lemon Grove, California • Oceanside, California + 23 more
- Conditions
- Episodic Migraine
- Interventions
- Atogepant, Ubrogepant
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 34 more
- Conditions
- Migraine
- Interventions
- Eptinezumab, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 892 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 14
- States / cities
- Walnut Creek, California • Gainesville, Florida • Maitland, Florida + 11 more
- Conditions
- Chronic Migraine in Children
- Interventions
- Eptinezumab, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 22
- States / cities
- New Haven, Connecticut • Stamford, Connecticut • Washington D.C., District of Columbia + 19 more
- Conditions
- Migraine Disorders
- Interventions
- Qudexy XR, Placebo
- Drug
- Lead sponsor
- Upsher-Smith Laboratories
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • La Jolla, California • Aurora, Colorado + 12 more
- Conditions
- Migraine
- Interventions
- Lu AG09222, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 874 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 28
- States / cities
- Hoover, Alabama • Carlsbad, California • Fullerton, California + 24 more
- Conditions
- Migraine
- Interventions
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 457 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 38
- States / cities
- San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 32 more
- Conditions
- Migraine Disorders
- Interventions
- ALD403 (Eptinezumab), Placebo
- Biological
- Lead sponsor
- Alder Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Treatment for Prevention of Chronic Migraine
- Interventions
- Erenumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 29
- States / cities
- Newport Beach, California • Palo Alto, California • Santa Monica, California + 25 more
- Conditions
- Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 862 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 80
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Carmichael, California + 72 more
- Conditions
- Migraine
- Interventions
- B244, Vehicle
- Biological
- Lead sponsor
- AOBiome LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 22
- States / cities
- Little Rock, Arkansas • Long Beach, California • Riverside, California + 19 more
- Conditions
- Migraine Prophylaxis
- Interventions
- E2007, Placebo
- Drug · Other
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 9
- States / cities
- Oceanside, California • Santa Monica, California • Tampa, Florida + 6 more
- Conditions
- Migraine
- Interventions
- Erenumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 31
- States / cities
- Long Beach, California • Los Angeles, California • Basalt, Colorado + 28 more
- Conditions
- Migraine
- Interventions
- Olanzapine during first intervention period and placebo during second intervention period, Placebo during first intervention period, then olanzapine during second intervention period
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Migraine, Episodic Migraine, Chronic Migraine, Headache
- Interventions
- CGRP antibody or gepant
- Drug
- Lead sponsor
- Hospital Universitari Vall d'Hebron Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Migraine Disorders
- Interventions
- Diet
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Migraine
- Interventions
- Fremanezumab
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 32
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Jacksonville, Florida + 27 more
- Conditions
- Migraine
- Interventions
- Rimegepant, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 18 more